Pharmacological Mechanisms and Target Discovery in Lung Injury-Driven Fibrosis: From Molecular Pathways to Preclinical Innovation
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 745
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue will delve into the molecular and pharmacological underpinnings of lung injury and fibrosis, focusing on non-clinical advancements. Potential topics include the following:
- Mechanistic Drivers: Signaling cascades (TGF-β, Wnt/β-catenin, DAMPs) connecting injury to fibroblast activation and extracellular matrix remodeling.
- Target Identification: AI- and multi-omics-guided discovery of novel targets (e.g., IL-11, epigenetic regulators, senescence-associated secretome).
- Drug Design: The structure-based optimization of small-molecule inhibitors, inhaled nanoparticle delivery systems, and senolytic agents.
- Preclinical Models: Advanced in vitro (e.g., 3D organoids) and in vivo systems to dissect injury–fibrosis interplay.
We invite the submission of reviews, original research, and methodological papers on molecular pharmacology, computational drug discovery, and experimental therapeutics. Contributions exploring environmental triggers (e.g., pollutants, toxins) and cross-disciplinary technologies (e.g., spatial transcriptomics, single-cell proteomics) are encouraged. This Special Issue will bridge mechanistic insights and innovative pharmacotherapeutic strategies in preclinical research.
Dr. Huifang Tang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung injury and fibrosis
- pharmacological mechanisms
- target discovery
- mechanistic drivers
- target identification
- drug design
- preclinical models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
